483. Antibiotic, Glucocorticoid, and Opioid Prescribing in Urgent Cares: An Opportunity for Reducing Medication Overuse.
作者: Shirley Cohen-Mekelburg.;Beth I Wallace.;Brooke Kenney.;Andrew Read.;Victoria C Weston.;Akbar K Waljee.
来源: Ann Intern Med. 2025年178卷10期1520-1523页 484. Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes : A Target Trial Emulation.
作者: Kosuke Inoue.;Debra Saliba.;Hiroshi Gotanda.;Tannaz Moin.;Carol M Mangione.;Alexandra M Klomhaus.;Yusuke Tsugawa.
来源: Ann Intern Med. 2025年178卷9期1258-1267页
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to decrease blood glucose levels, promote weight loss, and prevent cardiovascular events. However, evidence is limited regarding their effect on dementia, although emerging observational studies, some with serious methodological limitations, have suggested large reductions in dementia associated with GLP-1RAs that may not be entirely causally related.
499. Vaporized Nicotine Products for Smoking Cessation Among People Experiencing Social Disadvantage : A Randomized Clinical Trial.
作者: Ryan J Courtney.;Bridget C Howard.;Daniel Barker.;Dennis Petrie.;Ron Borland.;Anthony Shakeshaft.;Coral Gartner.;Colin Mendelsohn.;Veronica C Boland.;Alexandra Henderson.;Robyn L Richmond.;Piotr Tutka.;Felix Naughton.;Wayne Hall.;Nicholas Zwar.;Michael Farrell.;Richard P Mattick.;Hayden McRobbie.
来源: Ann Intern Med. 2025年178卷8期1085-1094页
Vaporized nicotine products (VNPs) are more effective than nicotine replacement therapy (NRT) for smoking cessation in general populations, but their effectiveness among low socioeconomic groups is largely unknown.
500. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.
作者: Yunha Noh.;Hui Yin.;Oriana H Y Yu.;Alain Bitton.;Laurent Azoulay.
来源: Ann Intern Med. 2025年178卷9期1268-1278页
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications used to treat type 2 diabetes and obesity, are associated with delayed gastric emptying, which is a risk factor for gastroesophageal reflux disease (GERD). However, evidence linking these drugs to GERD is limited.
|